{"filings":[{"id":668436,"accession_number":"0001213900-26-061039","cik":1139685,"company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","form_type":"8-K","filed_at":"2026-05-26T20:28:45+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"20/20 Biolabs reduces stockholder meeting quorum from majority to one-third","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted Amendment No. 1 to Bylaws on May 19, 2026.","Quorum required for stockholder meetings reduced from majority to one-third of outstanding shares.","Amendment to Section 2.5 of Amended and Restated Bylaws; effective immediately.","No other changes to stockholder rights or company governance structure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":10152048.837600002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":554518,"accession_number":"0001213900-26-059526","cik":1139685,"company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","form_type":"8-K","filed_at":"2026-05-20T20:10:53+00:00","items":["2.02","9.01"],"status":"ready","headline":"20/20 BioLabs Q1 revenue $0.4M, net loss $2.2M; expects Q2 rebound from firefighter programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $0.4M vs $0.6M YoY; net loss $2.2M vs $0.8M; gross margin 17.8% vs 29.9%.","Cash $4.2M (vs $1.0M Dec 2025) after $5M private placement; deferred revenue $0.5M.","State-funded firefighter cancer screening programs expected to drive meaningful Q2 revenue; second state committed.","Launched OneTest for Longevity with IBM; exclusive U.S. CKD license from ROKIT Healthcare.","Medicare MCED Screening Act signed Feb 2026; pathway for Medicare coverage by 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":353375.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10152048.837600002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91526,"accession_number":"0001213900-26-048257","cik":1139685,"company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"20/20 Biolabs cuts warrant exercise price to $2.25, from $11.42/$8.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On April 23, 2026, amended Streeterville warrants lowering exercise price to $2.25/share.","Warrants cover 3,627,627 shares; prior prices were $11.42 and $8.00.","Company retains right to terminate amendment within 90 days on 2 days' notice.","Warrants issued in conjunction with $5M+ in convertible notes and Series E preferred.","Reduction implies significant potential dilution for existing common shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":10152048.837600002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91525,"accession_number":"0001213900-26-037770","cik":1139685,"company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"20/20 BioLabs FY 2025 revenue $2.0M (+17%); gross margin expands; $5M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.0M (+17% YoY); gross profit $0.6M (+68%); gross margin 29.6% vs 20.6%.","Operating expenses down 35% to $3.9M; net loss improved 33% to ($3.7)M; cash $1.0M.","Completed $5.0M private placement Feb 2026; up to $40M available in tranches.","MDH awarded $520K to 18 fire departments for OneTest MCED; Medicare MCED pathway law signed Feb 2026.","Launched OneTest for Longevity with IBM AI; exclusive license with ROKIT Healthcare for CKD prediction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10152048.837600002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}